Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04196101 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

A Phase 2 study of Respiratory Syncytial Virus, sponsored by Enanta Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
82
Enrollment target
20
Study locations

NCT04196101 is a Phase 2 study of Respiratory Syncytial Virus that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 82 participants, below the 385-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04196101, a Phase 2 study of Respiratory Syncytial Virus, has completed, sponsored by Enanta Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
82 participants
Enrollment target
20
Study locations

Study Summary

This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

Conditions Studied

Respiratory Syncytial Virus

Interventions

  • DRUG Placebo
  • DRUG EDP-938

Study Locations (20)

Other

  • Instituto Medico Platense - Buenos Aires
  • Multiprofile Hospital for Active Treatment Puls - Blagoevgrad
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD - Haskovo
  • Medical Center Zdrave-1 OOD - Kozloduy
  • Medical Center Tara OOD - Veliko Tarnovo
  • Lakeland Clinical Trials - Waikato - Hamilton

North Carolina

  • Carolina Research Center - Shelby
  • PMG Research of Wilmington - Wilmington
  • Progressive Medicine of the Triad, LLC - Winston-Salem

Alabama

  • Central Alabama Research - Birmingham
  • Cahaba Research Inc. - Birmingham - Pelham

California

  • Saint Joseph's Clinical Research - Anaheim
  • Torrance Clinical Research Institute - Lomita

Nebraska

  • Pioneer Clinical Research LLC - Bellevue
  • Meridian Clinical Research - Norfolk

Sofia-Grad

  • Diagnostic and Consulting Center Aleksandrovska EOOD - Sofia
  • Medical Center Hera - Sofia

Florida

  • Miami Clinical Research - ClinEdge - PPDS - Miami

Nevada

  • Clinical Research of South Nevada - Las Vegas

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2020-01-22
Est. Completion 2022-01-04
Phase Phase 2

Sponsor

Enanta Pharmaceuticals

36 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04196101

The ClinicalTrials.gov registry entry for NCT04196101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 385-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (79% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04196101 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, North Carolina, Alabama.

Frequently Asked Questions

What is clinical trial NCT04196101 about?

NCT04196101 is a clinical study titled "A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects". This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

What is the current status of trial NCT04196101?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2020-01-22. Estimated completion is 2022-01-04.

What conditions does trial NCT04196101 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus.

What interventions are being tested in trial NCT04196101?

The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG).

Who is sponsoring clinical trial NCT04196101?

This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04196101 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Respiratory Syncytial Virus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.